Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06193889 · ClinicalTrials.gov registry record · Phase 2
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
A Phase 2 study of Myasthenia Gravis and Generalized Myasthenia Gravis, sponsored by Kyverna Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 14
- Study locations
NCT06193889: Recruiting Phase 2 study of Myasthenia Gravis and Generalized Myasthenia Gravis, sponsored by Kyverna Therapeutics.
NCT06193889 is a Phase 2 study of Myasthenia Gravis and Generalized Myasthenia Gravis that is actively recruiting participants, run by Kyverna Therapeutics. The registered enrollment target is 66 participants, below the 189-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (65% lower). The trial reports 14 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06193889, a Phase 2 study of Myasthenia Gravis and Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by Kyverna Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 14
- Study locations
Study Summary
A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis
Conditions Studied
Interventions
- DRUG Standard lymphodepletion regimen
- DRUG Standard of Care Treatment
- BIOLOGICAL KYV-101
Study Locations (14)
Other
- Hospital Israelita Albert Einstein - São Paulo
- Charite- Universitätsklinikum Berlin - Berlin
- Universitätsklinikum der Ruhr-Universität Bochum - Bochum
- Universitätsklinikum Hamburg-Eppendorf - Hamburg
- Medizinische Hochscule Hannover - Hanover
- Friedrich-Schiller-Universität Jena - Jena
- Universitätsklinik Magdeburg - Magdeburg
California
- University of California, Irvine - Orange
- Stanford University Medical Center - Palo Alto
Florida
- University of Miami - Miami
Indiana
- Indiana University Health - Indianapolis
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Texas
- Houston Methodist Hospital - Houston
Utah
- Intermountain Medical Center - Murray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2024-08-28 |
| Est. Completion | 2028-09 |
| Phase | Phase 2 |
What NCT06193889 shows while recruiting
NCT06193889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 189-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Myasthenia Gravis appearing as the primary indexed condition, and to 3 interventions - of which Standard lymphodepletion regimen is the first listed.
NCT06193889 lists 14 locations in 7 states (Other, California, Florida).
Frequently Asked Questions
What is clinical trial NCT06193889 about?
NCT06193889 is a clinical study titled "KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis". A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis
What is the current status of trial NCT06193889?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2024-08-28. Estimated completion is 2028-09.
What conditions does trial NCT06193889 study?
This clinical trial studies the following conditions: Myasthenia Gravis, Generalized Myasthenia Gravis.
What interventions are being tested in trial NCT06193889?
The interventions under investigation include: Standard lymphodepletion regimen (DRUG), Standard of Care Treatment (DRUG), KYV-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06193889?
This trial is sponsored by Kyverna Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06193889 being conducted?
This trial has 14 study locations across California, Florida, Indiana, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06193889's enrollment target sits among peer trials
66 21st of 32 higher than 12 of 32 other Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
RECRUITING · Phase 2
-
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
RECRUITING · Phase 2
-
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
COMPLETED · Phase 2
-
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
COMPLETED · Phase 2
-
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI